Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Almirall S.A., Ronda General Mitre, 151, 08022 Barcelona, Spain
Pharmacotherapeutic group: Opioids, Other Opioids
ATC Code: N02AX
Meptid (meptazinol) is a centrally acting analgesic belonging to the hexahydroazepine series, which has demonstrated mixed agonist and antagonist activity at opioid receptors.
Receptor binding studies have shown that although meptazinol displays only a low affinity for ÎŽ and Îș opioid receptor sites, it has a somewhat higher affinity for a subpopulation of ÎŒ sites. These binding sites also display a high affinity for the endogenous opioid peptides, and are thought to be responsible for, among other things, analgesia, but not for the mediation of respiratory depression.
A component of its analgesic action is also attributable, in mice at least, to an effect on central cholinergic transmission. In this respect it differs from all conventional analgesic drugs which have been examined.
After oral administration, meptazinol is rapidly absorbed and peak plasma levels are reached within 90 minutes. The plasma elimination half-life is variable (1.4-4 hours). The peak analgesic effect is seen within 30-60 minutes and lasts about 3-4 hours.
The drug is rapidly metabolised to the glucronide, and mostly excreted in the urine.
Standard toxicity tests revealed no unexpected findings of clinical significance.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
